MCID: LCH002
MIFTS: 53

Lichen Planus

Categories: Genetic diseases, Immune diseases, Oral diseases, Rare diseases, Skin diseases

Aliases & Classifications for Lichen Planus

MalaCards integrated aliases for Lichen Planus:

Name: Lichen Planus 12 74 36 54 15 17 71 32
Lichen, Ruber Planus 12
Lichen Ruber Planus 12

Classifications:



External Ids:

Disease Ontology 12 DOID:9201
KEGG 36 H01654
ICD9CM 34 697.0
NCIt 49 C3189
SNOMED-CT 67 4776004
ICD10 32 L43 L43.9
UMLS 71 C0023646

Summaries for Lichen Planus

KEGG : 36 Lichen planus (LP) is a chronic inflammatory and immune mediated skin disease with characteristic clinical and histopathologic features. The skin and oral mucosa are the most frequently involved areas. Other mucous membranes (including the genitalia, esophagus, and conjunctiva) and skin appendages (e.g., scalp hair and nails) can also be affected. The etiology and pathogenesis of LP remain unclear. An autoimmune reaction in which CD8+-T lymphocytes attack basal keratinocytes leading to apoptosis of the cells has been favored. Various potential triggers, e.g. viral or bacterial antigens, metal ions, drugs or physical factors, could initiate the autoimmune process. Nonetheless, the role of the individual trigger factors is controversial. There is a significant association between lichen planus and infection with hepatitis C virus (HCV). The diagnosis of LP is based on the clinical presentation and should be confirmed by biopsy, if suspected. Histopathology is often conclusive, but in vesiculobullous cutaneous LP or erosive oral LP, direct immunofluorescence (DIF) studies can be an integral step in differentiating between LP and other diseases. With few exceptions, all forms of LP are treated with the same measures. Depending on the severity of the findings, topical and systemic treatment options are available.

MalaCards based summary : Lichen Planus, also known as lichen, ruber planus, is related to lichen planus pemphigoides and graft-versus-host disease, and has symptoms including pruritus An important gene associated with Lichen Planus is COL17A1 (Collagen Type XVII Alpha 1 Chain), and among its related pathways/superpathways are Developmental Biology and Measles. The drugs Betamethasone and Pimecrolimus have been mentioned in the context of this disorder. Affiliated tissues include skin, tongue and t cells, and related phenotype is Increased gamma-H2AX phosphorylation.

Disease Ontology : 12 A lichen disease that is located in skin, located in tongue or located in oral mucosa, which presents itself in the form of papules, lesions or rashes.

Wikipedia : 74 Lichen planus (LP) is a chronic inflammatory and immune-mediated disease that affects the skin, nails,... more...

Related Diseases for Lichen Planus

Diseases in the Lichen Planus family:

Lichen Planus, Familial Rare Lichen Planus

Diseases related to Lichen Planus via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 685)
# Related Disease Score Top Affiliating Genes
1 lichen planus pemphigoides 35.4 DST COL17A1
2 graft-versus-host disease 31.9 TNF IFNG GZMB
3 candidiasis 31.7 TNF IFNG DEFB4A CXCL8
4 exanthem 31.7 TNF IFNG CXCL8
5 leukoplakia 31.7 KRT13 KRT1 DEFB4A
6 stomatitis 31.6 TNF MX1 IFNG CXCL8
7 herpes zoster 31.5 TNF IFNG COL17A1
8 gingivitis 31.4 TNF IFNG ICAM1 DEFB4A CXCL8
9 ulcerative colitis 31.4 TNF IFNG ICAM1 CXCL8
10 hepatitis b 31.3 TNF MX1 IFNG CXCL8
11 pemphigus 31.2 TNF DST DSG3 COL17A1
12 allergic hypersensitivity disease 31.2 TNF IFNG ICAM1 GZMB CXCL8
13 vaginitis 31.2 TNF DEFB4A CXCL8
14 esophagitis 31.2 TNF IVL CXCL8
15 periodontitis 31.2 TNF IFNG ICAM1 DEFB4A CXCL8
16 hepatitis a 31.1 TNF IFNG CXCL8
17 erythema multiforme 31.1 TNF IFNG ICAM1 GZMB CXCR3 CXCL8
18 proteasome-associated autoinflammatory syndrome 1 31.1 TNF IFNG ICAM1 CXCL8
19 rosacea 31.1 TNF DEFB4A CXCL8
20 keratosis 31.0 KRT10 KRT1 IVL FLG DST
21 amebiasis 31.0 TNF ICAM1 CXCL8
22 linear iga disease 31.0 DST COL17A1
23 pericarditis 31.0 TNF IFNG CXCL8
24 paraneoplastic pemphigus 30.9 DST DSG3 COL17A1
25 conjunctivitis 30.9 TNF IFNG ICAM1 CXCL9 CXCL8
26 epidermolysis bullosa acquisita 30.9 LAMC2 DST COL17A1
27 cicatricial pemphigoid 30.9 LAMC2 DST COL17A1
28 autoimmune disease 30.9 TNF ITGAL IFNG DSG3 CXCR3 CXCL8
29 guttate psoriasis 30.9 ITGAL IFNG
30 seborrheic dermatitis 30.9 TNF FLG DEFB4A
31 peptic ulcer disease 30.9 TNF DEFB4A CXCL8
32 cryoglobulinemia 30.9 TNF IFNG CXCL9
33 aphthous stomatitis 30.8 TNF IFNG DSG3 CXCL8
34 celiac disease 1 30.8 TNF IFNG GZMB CXCL8
35 keratoconjunctivitis 30.8 TNF IFNG ICAM1 CXCL9 CXCL8
36 cutaneous lupus erythematosus 30.8 TNF MX1 IFNG ICAM1 CXCR3
37 mumps 30.8 TNF MX1 IFNG CXCL8
38 poliomyelitis 30.8 TNF IFNG ICAM1
39 toxic shock syndrome 30.7 TNF IFNG CXCL8
40 urethritis 30.7 TNF DEFB4A CXCL8
41 folliculitis 30.7 TNF IFNG DEFB4A
42 hashimoto thyroiditis 30.6 TNF ITGAL IFNG ICAM1 CXCR3
43 pemphigus vulgaris, familial 30.6 IVL DST DSG3 COL17A1
44 sarcoidosis 1 30.6 TNF IFNG ICAM1 CXCR3 CXCL9
45 pemphigoid gestationis 30.6 DST DSG3 COL17A1
46 herpes simplex virus keratitis 30.6 ICAM1 CXCL8
47 osteomyelitis 30.5 TNF IFNG CXCL8
48 crohn's colitis 30.5 TNF IFNG DEFB4A CXCL8
49 food allergy 30.5 TNF IFNG FLG CXCL8
50 allergic contact dermatitis 30.5 TNF IFNG ICAM1 FLG DEFB4A CXCR3

Graphical network of the top 20 diseases related to Lichen Planus:



Diseases related to Lichen Planus

Symptoms & Phenotypes for Lichen Planus

UMLS symptoms related to Lichen Planus:


pruritus

GenomeRNAi Phenotypes related to Lichen Planus according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased gamma-H2AX phosphorylation GR00053-A 9.32 COL17A1 CXCL9 CXCR3 DEFB4A DSG3 IVL

Drugs & Therapeutics for Lichen Planus

Drugs for Lichen Planus (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 158)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
2
Pimecrolimus Approved, Investigational Phase 4 137071-32-0 17753757 6447131
3 Lycopene Approved, Investigational Phase 4 502-65-8 53477748
4
Glucosamine Approved, Investigational Phase 4 3416-24-8 439213
5
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
6
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
7
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
8
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
9 Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
10
Lactitol Approved, Investigational Phase 4 585-88-6, 585-86-4 493591
11
Chlorhexidine Approved, Vet_approved Phase 4 55-56-1 9552079 2713
12
Zinc Approved, Investigational Phase 4 7440-66-6 32051
13
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
14
Pomegranate Experimental, Investigational Phase 4
15
Chitosan Experimental Phase 4 9012-76-4 71853
16
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
17 Calcineurin Inhibitors Phase 4
18 Respiratory System Agents Phase 4
19 Anti-Asthmatic Agents Phase 4
20 Betamethasone sodium phosphate Phase 4
21 Betamethasone benzoate Phase 4
22 Betamethasone Valerate Phase 4 2152-44-5
23 Betamethasone-17,21-dipropionate Phase 4
24 Analgesics, Non-Narcotic Phase 4
25 Analgesics Phase 4
26 Dermatologic Agents Phase 4
27 Antirheumatic Agents Phase 4
28 Anti-Inflammatory Agents, Non-Steroidal Phase 4
29 Protective Agents Phase 4
30 Radiation-Protective Agents Phase 4
31 Antineoplastic Agents, Hormonal Phase 4
32 Methylprednisolone Acetate Phase 4
33 Chlorhexidine gluconate Phase 4
34 Anesthetics Phase 4
35 Anesthetics, Local Phase 4
36 Sodium Channel Blockers Phase 4
37 Anti-Arrhythmia Agents Phase 4
38 Diuretics, Potassium Sparing Phase 4
39
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
40
Fluoxymesterone Approved, Illicit Phase 2, Phase 3 76-43-7 6446
41
Minocycline Approved, Investigational Phase 3 10118-90-8 5281021
42
Terbinafine Approved, Investigational, Vet_approved Phase 3 91161-71-6 5402 1549008
43
Itraconazole Approved, Investigational Phase 3 84625-61-6 55283
44
Ibuprofen Approved Phase 2, Phase 3 15687-27-1 3672
45
Clobetasol Approved, Experimental, Investigational Phase 2, Phase 3 25122-41-2, 25122-46-7 32798 5311051
46
Nystatin Approved, Vet_approved Phase 2, Phase 3 1400-61-9 11953884
47
Petrolatum Approved, Investigational Phase 3 8009-03-8
48
Sirolimus Approved, Investigational Phase 3 53123-88-9 5284616 6436030 46835353
49 Hormones Phase 3
50 Hormone Antagonists Phase 3

Interventional clinical trials:

(show top 50) (show all 117)
# Name Status NCT ID Phase Drugs
1 Evaluation of Topical Pomegranate Extracts in Management of Oral Lichen Planus (A Randomized Clinical Trial) Completed NCT04193748 Phase 4 Topical pomegranate seeds and peel extracts
2 Glucosamine as a Novel Adjunctive Therapy in Oral Lichen Planus: A Pilot, Randomized, Clinical and Immunohistochemical Trial Completed NCT02858297 Phase 4 Glucosamine sulfate;triamcinolone acetonide
3 Comparative Study of the Efficacy of Lycopene Versus Prednisolone in the Management of Oral Lichen Planus: A Randomized, Double Blind Clinical Trial Completed NCT02587117 Phase 4 lycopene;Prednisolone
4 A Comparative Clinical and Immunohistochemical Study Between Topical Pimecrolimus and Corticosteroid in Treatment of Oral Lichen Planus Completed NCT02443311 Phase 4 Pimecrolimus 1% cream;Betamethasone 17-valerate 0.1% cream
5 Management of Pain in Oral Lichen Planus Patients: A Comparative Pilot Study Completed NCT03572959 Phase 4 0.1 % topical triamcinolone acetonide
6 Comparative Evaluation of Effect of Oral Zinc Supplementation and Placebo as an Adjuvant to Topical Corticosteroid Therapy in Oral Lichen Planus Patients Recruiting NCT04278599 Phase 4 Oral Zinc supplementation;Oral placebo supplementation
7 The Use of Local Anesthetic in Intralesional Corticosteroid Injections; A Randomized, Double Blind Controlled Trial Recruiting NCT03630198 Phase 4 Corticosteroid with lidocaine;Corticosteroid with normal saline
8 Effectiveness of Mucolox® and Clonazepam in Treatment of Burning Mouth Syndrome Withdrawn NCT02690844 Phase 4 Clonazepam mixed with Mucolox®;Mucolox® alone;Clonazepam
9 A Study of Topical Hexaminolevulinate (HAL) Photodynamic Therapy (PDT) and a Phase III Comparative Treatment Study of HAL PDT in Female Genital Erosive Lichen Planus (GELP) Unknown status NCT01282515 Phase 2, Phase 3 clobetasolpropionate;hexaminolevulinate
10 The Efficacy of Topical Minocycline in Managing Symptomatic Oral Lichen Planus. A Randomized Controlled Trial Unknown status NCT01083420 Phase 3 Minocycline;Dexamethasone
11 Comparative Study of Systemic Antifungal Drugs Used in Treatment of Onychomycosis Unknown status NCT03171584 Phase 3 Terbinafine
12 Randomized Placebo-Controlled Clinical Pilot Trial Regarding the Efficacy of Elidel Cream on Erosive Oral Lichen Planus Completed NCT00130572 Phase 3 Pimecrolimus
13 Evaluation of Systemic Administration of Green Tea Polyphenols as a Supportive Antioxidant Agent in the Management of Oral Lichen Planus Completed NCT02329600 Phase 3 green tea tablets (Green tea extract 5:1) 200 mg;Triamcinolone Acetonide
14 Chamaemelum Nobile 2% Versus Placebo Topic Gel to Treatment Oral LichenPlanus Completed NCT02421770 Phase 3
15 Use of Topical Non-Steroidal Anti- Inflammatory to Reduce Pain in Oral Lichen Planus and Oral Lichenoid Lesions. Completed NCT03509675 Phase 2, Phase 3 Ibuprofen suspension 5mg/100ml;Placebos
16 Efficacy of Topical Treatment With Clobetasol in Symptomatic Oral Lichen Planus. A Multicenter Placebo-controlled Randomized Clinical Trial. Not yet recruiting NCT04364555 Phase 2, Phase 3 Clobetasol Propionate;Placebo/active;Placebo/placebo
17 Efficacy of Topical Rapamycin in Treatment of Chronic Erosive Oral Lichen Planus. Double Blind Randomised Controlled Trial Rapamycin vs Topical Steroids Terminated NCT01061853 Phase 3 TOPICAL SIROLIMUS (RAPAMUNE*);TOPICAL BETAMETHASONE 0.05%
18 A Randomized Clinical Trial of the Effect of Pimecrolimus Cream 1% Compared With Topical Corticosteroid in Treatment of Erosive Oral Lichen Planus Unknown status NCT01524744 Phase 2 Pimecrolimus ointment;Adcortyl
19 A Comparative Study on Clinical Efficacy of Clobetasol and Betamethasone in Orabase in Combination With Clotrimazole, in Oral Lichen Planus Unknown status NCT03026478 Phase 2 Betamethasone Dipropionate;Clobetasol Propionate
20 An Open-Label Pilot Study to Evaluate the Safety and Efficacy of Apremilast (CC-10004) in the Treatment of Moderate to Severe Lichen Planus Unknown status NCT01041625 Phase 2 Apremilast (CC-10004)
21 Single-Center, Prospective, Open Label, Single-arm Pilot Study Investigating the Efficacy and Safety of Alitretinoin in Patients Suffering From Severe Mucosal Lichen Planus. Unknown status NCT01538732 Phase 2 alitretinoin
22 Dexamethasone Solution and Dexamethasone in Mucolox™ for the Treatment of Oral Lichen Planus Unknown status NCT02850601 Phase 2 Dexamethasone
23 Efficacy of Intralesional Injection of Autologous Platelet Rich Plasma Versus Intralesional Injection of Corticosteroids on Pain Relief and Ulcers Healing in Patients With Erosive Oral Lichen Planus; Randomized Clinical Trial Unknown status NCT03293368 Phase 2 Triamcinolone Acetonide
24 Cedar Honey in Treatment of Oral Lichen Planus: a Randomized Clinical Trial Completed NCT01974414 Phase 1, Phase 2 orally administered cedar honey
25 Comparison of Tacrolimus 0.1% and Clobetasol 0.05% in the Management of Symptomatic Oral Lichen Planus- A Double-blinded Randomized Clinical Trial in Sri Lanka Completed NCT02744378 Phase 2 Tacrolimus 0.1%;Clobetasol 0.05%
26 Study of Metronidazole and Doxycycline to Treat Oral Lichen Planus and to Compare Their Efficacy With Each Other Completed NCT00484250 Phase 2 metronidazole,doxycycline
27 Efficacy of Oral Lycopene in the Management of Oral Lichen Planus Completed NCT00656214 Phase 2 Lycopene;Placebo
28 A 6-week Randomized, Double-blind, Vehicle-controlled Pilot Study With a 6-week Open Label Extension to Assess the Efficacy and Safety of Pimecrolimus 1% Cream in the Treatment of Oral Lichen Planus Completed NCT00297037 Phase 2 Pimecrolimus 1% cream
29 A Randomized, Placebo-Controlled, Double-Blind Trial of a Two Week Course of Curcuminoids in Oral Lichen Planus Completed NCT00525421 Phase 2 Curcuminoids;Placebo
30 The Efficacy of Omega-3 in Treatment of Atrophic/Erosive Lichen Planus and Improvement of Quality of Life: A Randomized, Double Blind, Controlled Study Completed NCT02106468 Phase 2 Prednisone tablet 5mg;Omega-3 soft capsules 1000 mg
31 Treatment of Oral Lichen Planus Lesions Completed NCT00746772 Phase 2 Purslane 235mg/day in one dosage;Placebo : one dosage
32 Hydroxychloroquine Versus Clobetasol 0.05% Rinse for the Treatment of Oral Lichen Planus Completed NCT00102557 Phase 2 Hydroxychloroquine
33 Dexamethasone 0.01% Solution for the Treatment of Oral Lichen Planus Completed NCT00111072 Phase 2 dexamethasone 0.01% solution
34 Effect of the Probiotic Bifidobacterium Animalis Subsp. Lactis HN019 on Clinical, Histopathological and Immunophenotypic Features of Oral Lichen Planus Completed NCT03386643 Phase 2 Bifidobacterium animalis subsp. lactis HN019;Clobetasol propionate 0.05%
35 Nonaromatic Naphthalan - Composition Study and Biological Effects on Epithelial Tissues Completed NCT02920658 Phase 2 NAVS Naphthalan;0.05% Betamethasone dipropionate
36 Comparison of Triamcinolone Acetonide Mucoadhesive Film and Licorice Mucoadhesive Film Effect on the Duration and Symptoms of Lesions That Caused by Symptomatic Oral Lichen Planus Completed NCT02453503 Phase 2 Licorice;Triamcinolone Acetonide
37 Open Label Phase 2 Proof-of-concept Pilot Trial of Topical Ruxolitinib in Repigmenting Adult Patients With Vitiligo Completed NCT02809976 Phase 2 Ruxolitinib 1.5% Phosphate Cream
38 Valchlor in the Treatment of Lichen Planopilaris: A Single Arm, Open‐ Label, Exploratory Study Completed NCT03417141 Phase 2 Valchlor
39 A Single Center, Investigator-blinded Study of the Efficacy of Topical Cyclosporine 0.05% Ophthalmic Suspension (RESTASIS®) Under Occlusion Versus Vehicle in the Treatment of Brittle Nail Syndrome Completed NCT01064830 Phase 2 topical cyclosporine ophthalmic suspension 0.05%;vehicle
40 The AP-GELP Study: A Randomized, Placebo-Controlled Clinical Trial on the Effects of Phosphodiesterase 4-Inhibitor Apremilast in Female Genital Erosive Lichen Planus Recruiting NCT03656666 Phase 2 Apremilast;Placebo
41 The APOLP Trial: A Single-Center, Randomized, 16 Weeks, Explanatory, Parallel-Group, Superiority, Blinded, Placebo-Controlled, Clinical Trial of Apremilast Use in Oral Lichen Planus Recruiting NCT03836885 Phase 2 Apremilast;Placebo
42 INCB018424 in the Treatment of Cutaneous Lichen Planus Recruiting NCT03697460 Phase 2 INCB018424
43 A Randomized, Double-blind, Placebo-controlled, Parallel Group Clinical Study to Assess the Safety and Efficacy of Three Doses of Clobetasol Propionate When Administered Intra-orally Twice Daily in Patients With Oral Lichen Planus (OLP) Using Rivelin®-CLO Patches Recruiting NCT03592342 Phase 2 Clobetasol Propionate
44 Phase II Study of Topical Ruxolitinib for Cutaneous Chronic Graft Versus Host Disease (cGVHD) Recruiting NCT03395340 Phase 2 Ruxolitinib 1.5% cream;Vehicle cream
45 KPL-716-C202: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Pilot Study to Investigate the Efficacy, Safety, and Tolerability of KPL-716 in Reducing Pruritus in Diseases Characterized by Chronic Pruritus Active, not recruiting NCT03858634 Phase 2 KPL-716;Placebo
46 Oral Low-Dose Naltrexone in the Treatment of Lichen Planopilaris and Frontal Fibrosing Alopecia; an Uncontrolled Open-label Prospective Study Active, not recruiting NCT04409041 Phase 2 Low-Dose Naltrexone
47 TOPical Sirolimus in linGUal Microcystic Lymphatic Malformation -TOPGUN Active, not recruiting NCT04128722 Phase 2 Sirolimus Oral Liquid Product 1mg/mL
48 A Proof of Concept Study to Evaluate the Efficacy, Safety and Tolerability of Secukinumab 300 mg Over 32 Weeks in Adult Patients With Biopsy-proven Forms of Lichen Planus Not Adequately Controlled With Topical Therapies - PRELUDE Not yet recruiting NCT04300296 Phase 2 Cutaneous lichen planus secukinumab 300 mg Q4W;Cutaneous lichen planus placebo;Mucosal lichen planus placebo;Lichen planopilaris placebo;Mucosal lichen planus secukinumab 300 mg Q4W;Lichen planopilaris secukinumab 300 mg Q4W
49 A Randomized, Placebo-Controlled, Double-Blind Clinical Trial of Curcuminoids in Oral Lichen Planus Terminated NCT00226174 Phase 2 Curcuminoids
50 A Randomized, Double-Blind, Placebo-Controlled Pilot Study of the Efficacy and Safety of Alefacept in the Treatment of Moderate to Severe Erosive Mucosal Lichen Planus Terminated NCT00135733 Phase 2 Amevive (Alefacept);Placebo

Search NIH Clinical Center for Lichen Planus

Genetic Tests for Lichen Planus

Anatomical Context for Lichen Planus

The Foundational Model of Anatomy Ontology organs/tissues related to Lichen Planus:

19
Skin, Tongue

MalaCards organs/tissues related to Lichen Planus:

40
Skin, T Cells, Tongue, Liver, Testes, Thyroid, Endothelial

Publications for Lichen Planus

Articles related to Lichen Planus:

(show top 50) (show all 7610)
# Title Authors PMID Year
1
T cells reactive with the NC16A domain of BP180 are present in vulval lichen sclerosus and lichen planus. 54 61
19686329 2010
2
Involvement of granzyme B and granulysin in the cytotoxic response in lichen planus. 61 54
18331568 2008
3
The expression of TNF-alpha and ICAM-1 in lesions of lichen planus and its implication. 54 61
18231758 2007
4
Cytokine alterations in lichen sclerosus: an immunohistochemical study. 54 61
17034521 2006
5
Collagen XVII/BP180: a collagenous transmembrane protein and component of the dermoepidermal anchoring complex. 54 61
16197389 2005
6
Cytotoxic molecule expression and epithelial cell apoptosis in oral and cutaneous lichen planus. 54 61
15151217 2004
7
Lichen planus and leukocytoclastic vasculitis induced by interferon alpha-2b in a subject with HCV-related chronic active hepatitis. 54 61
12705750 2003
8
Comparison of the distribution and numbers of antigen-presenting cells among T-lymphocyte-mediated dermatoses: CD1a+, factor XIIIa+, and CD68+ cells in eczematous dermatitis, psoriasis, lichen planus and graft-versus-host disease. 61 54
12373334 2002
9
Oral lichen planus: an update. 54 61
12582419 2002
10
Topical retinaldehyde treatment in oral lichen planus and leukoplakia. 61 54
12779246 2002
11
Upregulation of human beta-defensin 2 peptide expression in oral lichen planus, leukoplakia and candidiasis. an immunohistochemical study. 54 61
12389997 2002
12
Presence of lichen planus during a course of interferon alpha-2a therapy for a viral chronic C hepatitis. 61 54
11694869 2001
13
Identification of the AgNORs, PCNA and ck16 proteins in oral lichen planus lesions. 54 61
11834097 2001
14
Differential expression of CXCR3 targeting chemokines CXCL10, CXCL9, and CXCL11 in different types of skin inflammation. 54 61
11523046 2001
15
Lichen planus exacerbation by interferon-alpha-2A for chronic viral hepatitis C. 61 54
19864712 2000
16
Lichenoid dermatitis in paraneoplastic pemphigus: a pathogenic trigger of epitope spreading? 61 54
10815859 2000
17
Lichen planus induced by interferon-alpha-2B therapy in a patient with cutaneous malignant melanoma. 61 54
10494726 1999
18
Autoantibodies in lichen planus pemphigoides react with a novel epitope within the C-terminal NC16A domain of BP180. 61 54
10417629 1999
19
Acquired skin disease of hemidesmosomes. 54 61
10379705 1999
20
Human IP-9: A keratinocyte-derived high affinity CXC-chemokine ligand for the IP-10/Mig receptor (CXCR3). 54 61
10233762 1999
21
BP180/type XVII collagen: its role in acquired and inherited disorders or the dermal-epidermal junction. 61 54
10335914 1999
22
C5a receptor and interleukin-6 are expressed in tissue macrophages and stimulated keratinocytes but not in pulmonary and intestinal epithelial cells. 54 61
10027407 1999
23
MIG is a dominant lymphocyte-attractant chemokine in lichen planus lesions. 54 61
9856808 1998
24
Keratin and involucrin expression in discoid lupus erythematosus and lichen planus. 54 61
9341972 1997
25
The role of granzyme B-expressing CD8-positive T cells in apoptosis of keratinocytes in lichen planus. 61 54
9341973 1997
26
Altered distribution and synthesis of laminin-5 (kalinin) in oral lichen planus, epithelial dysplasias and squamous cell carcinomas. 54 61
9115910 1997
27
Lichen planus and chronic hepatitis C: exacerbation of the lichen under interferon-alpha-2a therapy. 54 61
8864684 1996
28
Vascular adhesion molecules in oral lichen planus. 54 61
8784900 1996
29
Destruction of the epithelial anchoring system in lichen planus. 61 54
7615961 1995
30
In three types of interface dermatitis, different patterns of expression of intercellular adhesion molecule-1 (ICAM-1) indicate different triggers of disease. 54 61
7616001 1995
31
Lichen planus induced by interferon-alpha-2a therapy for chronic active hepatitis C. 61 54
7600144 1995
32
Alteration of cytokeratin expression in oral lichen planus. 54 61
7542150 1995
33
Expression of MxA protein in inflammatory dermatoses. 54 61
7822763 1995
34
Analysis of mast cell subpopulations (MCT, MCTC) in cutaneous inflammation using novel enzyme-histochemical staining techniques. 54 61
7538409 1994
35
Immunofluorescent analysis of the basement membrane zone in lichen planus suggests destruction of the lamina lucida in bullous lesions. 54 61
8040461 1994
36
Increased submucosal factor XIIIa-positive dendrocytes in oral lichen planus. 54 61
7517451 1994
37
Lymphocyte and macrophage subsets in active and inactive lesions of lichen planus. 54 61
8100122 1993
38
Epidermal dendritic cells in psoriasis possess a phenotype associated with antigen presentation: in situ expression of beta 2-integrins. 61 54
1401271 1992
39
Expression of the CD54 (ICAM-1) and CD11a (LFA-1) adhesion molecules in oral mucosal inflammation. 54 61
1348286 1992
40
Elastolysis in lichen ruber planus. 54 61
1681662 1991
41
[Lichen planus: etiopathogenesis]. 61 54
1983174 1990
42
Cytokine modulation of adhesion molecules in the regulation of immunologic cytotoxicity of epidermal targets. 61 54
2258627 1990
43
Induction and upregulation of adhesion receptors in oral and dermal lichen planus. 61 54
1981078 1990
44
Lichen planus pemphigoides: case report and results of immunofluorescence and immunoelectron microscopic study. 61 54
2180994 1990
45
Immunohistochemical studies on fibrillin in amyloidosis, lichen ruber planus and porphyria. 61 54
1699374 1990
46
Etretinate suppresses ICAM-1 expression by lesional keratinocytes in healing cutaneous lichen planus. 54 61
1979727 1990
47
The influence of interferon on healthy and diseased skin. 61
30527631 2020
48
Total glucosides of paeony: A review of its phytochemistry, role in autoimmune diseases, and mechanisms of action. 61
32371143 2020
49
Antiviral therapy against chronic hepatitis C is associated with a reduced risk of oral cancer. 61
31853972 2020
50
HIF1α/PLD2 axis linked to glycolysis induces T-cell immunity in oral lichen planus. 61
32205175 2020

Variations for Lichen Planus

Expression for Lichen Planus

Search GEO for disease gene expression data for Lichen Planus.

Pathways for Lichen Planus

Pathways related to Lichen Planus according to GeneCards Suite gene sharing:

(show all 28)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.41 TNF KRT16 KRT13 KRT10 KRT1 IVL
2
Show member pathways
12.68 TNF MX1 ITGAL IFNG ICAM1 CXCL8
3
Show member pathways
12.66 LAMC2 ITGAL ICAM1 DST COL17A1
4
Show member pathways
12.65 TNF ITGAL IFNG ICAM1 GZMB CXCL9
5
Show member pathways
12.41 TNF ITGAL IFNG ICAM1 GZMB
6
Show member pathways
12.26 TNF IFNG DEFB4A CXCL8
7
Show member pathways
12.25 TNF CXCR3 CXCL9 CXCL8
8
Show member pathways
12.15 KRT16 KRT13 KRT10 KRT1 IVL FLG
9
Show member pathways
12.1 TNF IFNG DEFB4A CXCL8
10 11.89 TNF IFNG ICAM1 CXCL8
11
Show member pathways
11.81 KRT16 KRT13 KRT1 DST
12 11.78 KRT1 IVL CXCL8
13 11.77 TNF LAMC2 IFNG CXCL8
14 11.72 IFNG ICAM1 CXCL8
15
Show member pathways
11.68 TNF IFNG CXCL8
16 11.64 TNF IFNG GZMB CXCR3
17 11.62 TNF ITGAL IFNG ICAM1 CXCL8
18
Show member pathways
11.57 TNF IFNG GZMB
19
Show member pathways
11.5 TNF IFNG ICAM1 CXCL8
20 11.46 TNF ICAM1 CXCL8
21 11.32 IFNG ICAM1 CXCL9
22 11.31 TNF IFNG ICAM1
23
Show member pathways
11.29 TNF IFNG GZMB
24 11.27 ITGAL IFNG ICAM1 CXCL8
25 11.23 ITGAL CXCR3 CXCL9
26 11.08 KRT16 KRT13 KRT10 ITGAL ICAM1 DEFB4A
27 11.05 TNF ITGAL IFNG ICAM1 CXCL8
28 10.93 TNF LAMC2 ITGAL CXCL9 CXCL8 COL17A1

GO Terms for Lichen Planus

Cellular components related to Lichen Planus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 10.02 TNF LAMC2 KRT10 KRT1 IFNG DEFB4A
2 extracellular space GO:0005615 9.85 TNF LAMC2 KRT10 KRT1 IFNG ICAM1
3 collagen-containing extracellular matrix GO:0062023 9.65 LAMC2 KRT1 ICAM1 FLG COL17A1
4 intermediate filament GO:0005882 9.43 KRT16 KRT13 KRT10 KRT1 FLG DST
5 hemidesmosome GO:0030056 9.32 DST COL17A1
6 cornified envelope GO:0001533 9.02 KRT10 KRT1 IVL FLG DSG3

Biological processes related to Lichen Planus according to GeneCards Suite gene sharing:

(show all 23)
# Name GO ID Score Top Affiliating Genes
1 cell adhesion GO:0007155 10.03 LAMC2 ITGAL ICAM1 DST DSG3 CXCR3
2 immune response GO:0006955 9.99 TNF IFNG DEFB4A CXCR3 CXCL9 CXCL8
3 extracellular matrix organization GO:0030198 9.89 TNF LAMC2 ITGAL ICAM1 COL17A1
4 cellular response to lipopolysaccharide GO:0071222 9.88 TNF ICAM1 CXCL9 CXCL8
5 inflammatory response GO:0006954 9.88 TNF KRT16 ITGAL CXCR3 CXCL9 CXCL8
6 chemotaxis GO:0006935 9.87 DEFB4A CXCR3 CXCL9 CXCL8
7 chemokine-mediated signaling pathway GO:0070098 9.77 CXCR3 CXCL9 CXCL8
8 defense response GO:0006952 9.77 TNF MX1 DEFB4A CXCL9 CXCL8
9 antimicrobial humoral immune response mediated by antimicrobial peptide GO:0061844 9.76 DEFB4A CXCL9 CXCL8
10 positive regulation of nitric oxide biosynthetic process GO:0045429 9.72 TNF IFNG ICAM1
11 keratinization GO:0031424 9.63 KRT16 KRT13 KRT10 KRT1 IVL DSG3
12 positive regulation of chemokine biosynthetic process GO:0045080 9.61 TNF IFNG
13 negative regulation of amyloid-beta clearance GO:1900222 9.61 TNF IFNG
14 establishment of skin barrier GO:0061436 9.61 KRT16 KRT1 FLG
15 positive regulation of interleukin-1 beta biosynthetic process GO:0050725 9.59 TNF IFNG
16 keratinocyte differentiation GO:0030216 9.56 KRT16 KRT10 IVL FLG
17 T cell activation via T cell receptor contact with antigen bound to MHC molecule on antigen presenting cell GO:0002291 9.54 ITGAL ICAM1
18 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.52 TNF IFNG
19 hemidesmosome assembly GO:0031581 9.5 LAMC2 DST COL17A1
20 positive regulation of vitamin D biosynthetic process GO:0060557 9.48 TNF IFNG
21 positive regulation of nitrogen compound metabolic process GO:0051173 9.46 TNF IFNG
22 peptide cross-linking GO:0018149 9.26 KRT10 KRT1 IVL FLG
23 cornification GO:0070268 9.17 KRT16 KRT13 KRT10 KRT1 IVL FLG

Molecular functions related to Lichen Planus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.11 TNF MX1 KRT16 KRT13 KRT10 KRT1
2 cytokine activity GO:0005125 9.56 TNF IFNG CXCL9 CXCL8
3 structural molecule activity GO:0005198 9.35 KRT16 KRT13 KRT10 FLG DST
4 structural constituent of epidermis GO:0030280 8.8 KRT10 KRT1 FLG

Sources for Lichen Planus

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....